Talk:Abnormal Development - Thalidomide: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
http://www.tga.gov.au/committee/acpm.htm | |||
In 2010, ADEC was replaced by the Advisory Committee on Prescription Medicines (ACPM). | |||
The Advisory Committee on Prescription Medicines (ACPM) was formed in January 2010. The ACPM advises and makes recommendations to the TGA on prescription medicines. This includes: | |||
inclusion of a prescription medicine on the Australian Register of Therapeutic Goods (the Register) | |||
changes to an entry of a prescription medicine on the Register | |||
removal or retention of a prescription medicine on the Register. | |||
Australian Drug Evaluation Committee was established in 1963 following the Thalidomide experience. | |||
[http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18418038 Knobloch J, Rüther U.] Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. Cell Cycle. 2008 Feb 14;7(9) | [http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18418038 Knobloch J, Rüther U.] Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. Cell Cycle. 2008 Feb 14;7(9) | ||
Revision as of 18:20, 16 Haziran 2010
http://www.tga.gov.au/committee/acpm.htm
In 2010, ADEC was replaced by the Advisory Committee on Prescription Medicines (ACPM).
The Advisory Committee on Prescription Medicines (ACPM) was formed in January 2010. The ACPM advises and makes recommendations to the TGA on prescription medicines. This includes:
inclusion of a prescription medicine on the Australian Register of Therapeutic Goods (the Register) changes to an entry of a prescription medicine on the Register removal or retention of a prescription medicine on the Register.
Australian Drug Evaluation Committee was established in 1963 following the Thalidomide experience.
Knobloch J, Rüther U. Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. Cell Cycle. 2008 Feb 14;7(9)
"Many hypotheses have been proposed to explain the molecular mechanism of thalidomide teratogenicity, in particular regarding to limb defects. Most experimental evidence in vivo has been provided for a model that suggests the generation of oxidative stress by thalidomide with subsequent down-regulation of Wnt and Akt survival pathways. ...We extend this model by presenting new data demonstrating an involvement of the transcription factors Tbx5 and Sall4 in thalidomide-induced molecular pathology."
Benegbi M. 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.
Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.
Chemotherapy
References
Reviews
McBride WG. Thalidomide embryopathy. Teratology. 1977 Aug;16(1):79-82.
Saunders EJ, Saunders JA. Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int. 1990;11(4):423-32.
Stephens TD. Proposed mechanisms of action in thalidomide embryopathy. Teratology. 1988 Sep;38(3):229-39.
Newman CG The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol. 1986 Sep;13(3):555-73.
Fletcher I. Review of the treatment of thalidomide children with limb defeciency in Great Britain. Clin Orthop Relat Res. 1980 May;(148):18-25.
Articles
Benegbi M. 45 years later...where do we stand? Can J Clin Pharmacol. 2007 Winter;14(1):e37-9.
"The Thalidomide Victims Association of Canada (TVAC) was founded in 1988 and is the only organization in North America to work with and for Thalidomide victims. Our mission is to empower our members and to improve their quality of life through various programs and customized services. With the return of Thalidomide on the market, TVAC also took on the mandate of informing the public on the devastating effects of this medication and to promote awareness and caution when using any teratogenic products currently available".
McBride WG. Prescription drugs in the first trimester and congenital malformations. Aust N Z J Obstet Gynaecol. 1992 Nov;32(4):386.
Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007;46(2):234-8.
Li PK, Pandit B, Sackett DL, Hu Z, Zink J, Zhi J, Freeman D, Robey RW, Werbovetz K, Lewis A, Li C. A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities. Mol Cancer Ther. 2006 Feb;5(2):450-6.
Search Pubmed Now: [TITL&doptcmdl=DocSum Thalidomide[TITL]] (2007: 2,672 Articles, 253 Reviews) | Drug use in pregnancy
Books on Thalidomide
A selection of recent general public information books on Thalidomide, available from various internet commercial suppliers (search using the book title). Please note that this listing does not reflect an endorsement of the book or its content and is provided for educational purposes only.
Thalidomide Kid (Paperback) by Kate, Rigby (Author)
Thalidomide - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References (Paperback) by ICON Health Publications (Author)
Internet supplier link: Amazon